These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 12800825)
41. Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir. TreatmentUpdate; 2004 Mar; 16(2):2-3. PubMed ID: 17219666 [No Abstract] [Full Text] [Related]
42. We want our Trizivir! Vázquez E Posit Aware; 2003; 14(5):25-6. PubMed ID: 14679938 [No Abstract] [Full Text] [Related]
43. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962 [TBL] [Abstract][Full Text] [Related]
44. [Valuable combination partner. Great benefit for therapy naive patients]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061 [No Abstract] [Full Text] [Related]
45. Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. Pialoux G; Fournier S; Moulignier A; Poveda JD; Clavel F; Dupont B AIDS; 1997 Aug; 11(10):1302-3. PubMed ID: 9256956 [No Abstract] [Full Text] [Related]
46. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642 [TBL] [Abstract][Full Text] [Related]
47. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
49. Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy. Katlama C; Gazzard B; Mallolas J; Schürmann D; Moroni M; Demonty N; Antoun Z; Gordon D AIDS; 2003 Aug; 17(12):1855-6. PubMed ID: 12891074 [TBL] [Abstract][Full Text] [Related]
50. Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults. Mallolas J; Pich J; Peñaranda M; Domingo P; Knobel H; Pedrol E; Gutiérrez F; Barrufet P; Peraire J; Asenjo MA; Vidal F; Gatell JM AIDS; 2008 Jan; 22(3):377-84. PubMed ID: 18195564 [TBL] [Abstract][Full Text] [Related]
51. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC; AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047 [TBL] [Abstract][Full Text] [Related]
52. Triple-nucleoside regimens versus efavirenz. De Luca A; Di Giambenedetto S N Engl J Med; 2004 Aug; 351(7):717-9; author reply 717-9. PubMed ID: 15306677 [No Abstract] [Full Text] [Related]
54. Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095. Feinberg J AIDS Clin Care; 2006 Nov; 18(11):99. PubMed ID: 17183745 [No Abstract] [Full Text] [Related]
55. Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. Kessler HA MedGenMed; 2005 Jun; 7(2):70. PubMed ID: 16369448 [TBL] [Abstract][Full Text] [Related]
56. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. Harrigan PR; Stone C; Griffin P; Nájera I; Bloor S; Kemp S; Tisdale M; Larder B J Infect Dis; 2000 Mar; 181(3):912-20. PubMed ID: 10720512 [TBL] [Abstract][Full Text] [Related]
57. A comparison of three initial antiretroviral AIDS regimens. Ribaudo HJ; Kuritzkes DR; Gulick RM N Engl J Med; 2007 Sep; 357(10):1056-7. PubMed ID: 17804858 [No Abstract] [Full Text] [Related]
58. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only? Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129 [TBL] [Abstract][Full Text] [Related]
59. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314 [TBL] [Abstract][Full Text] [Related]
60. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]